Atara Biotherapeutics (ATRA) Competitors

Oric Pharmaceuticals (NASDAQ:ORIC) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Which has more risk & volatility, ORIC or ATRA?

Oric Pharmaceuticals has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500. Comparatively, Atara Biotherapeutics has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500.

Which has better earnings and valuation, ORIC or ATRA?

Atara Biotherapeutics has higher revenue and earnings than Oric Pharmaceuticals. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$127.85M	-$1.89	-5.57
Atara Biotherapeutics	$128.94M	0.64	-$85.40M	-$0.43	-27.40

Does the media refer more to ORIC or ATRA?

In the previous week, Oric Pharmaceuticals had 7 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 10 mentions for Oric Pharmaceuticals and 3 mentions for Atara Biotherapeutics. Oric Pharmaceuticals' average media sentiment score of 1.08 beat Atara Biotherapeutics' score of 0.96 indicating that Oric Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atara Biotherapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend ORIC or ATRA?

Oric Pharmaceuticals presently has a consensus price target of $17.29, indicating a potential upside of 64.31%. Atara Biotherapeutics has a consensus price target of $21.00, indicating a potential upside of 78.27%. Given Atara Biotherapeutics' higher possible upside, analysts plainly believe Atara Biotherapeutics is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Atara Biotherapeutics	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.80

Do insiders & institutionals believe in ORIC or ATRA?

95.1% of Oric Pharmaceuticals shares are owned by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are owned by institutional investors. 6.8% of Oric Pharmaceuticals shares are owned by insiders. Comparatively, 4.0% of Atara Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Is ORIC or ATRA more profitable?

Atara Biotherapeutics has a net margin of 3.07% compared to Oric Pharmaceuticals' net margin of 0.00%. Atara Biotherapeutics' return on equity of -8.34% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-51.75%	-47.09%
Atara Biotherapeutics	3.07%	-8.34%	6.61%

Summary

Oric Pharmaceuticals and Atara Biotherapeutics tied by winning 8 of the 16 factors compared between the two stocks.